Recently, an AO-mediated gene suppression approach was evaluated for its potential as a substrate reduction therapy for Pompe disease (Glycogen storage disease type II; OMIM#232300), a LSD caused by a deficiency of acid alpha-glucosidase (GAA; EC 3.2.1.20). This evidence concerns the gene GAA and glycogen storage disease II.